Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2018
Event: Resubmission of New Drug Application (NDA) for DEXTENZA (dexamethasone insert) 0.4mg to the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Regulatory Action: The Company resubmitted its NDA for DEXTENZA to address manufacturing deficiencies cited in a July 2017 Complete Response Letter from the FDA.
- Product Indication: The application is for the treatment of ocular pain following ophthalmic surgery.
Guidance, Outlook, and Risks
Management Outlook
- Review Designation: The Company anticipates the resubmission will receive a Class 2 (six-month review) designation.
- Target Action Date: The Company expects a target action date under the Prescription Drug User Fee Act by the end of 2018.
Risks and Contingencies
- Forward-Looking Statements: The filing includes extensive disclaimers regarding future expectations, noting that actual results may differ materially due to risks in clinical development, regulatory approvals, and commercialization.
- Specific Risks: Risks include the timing and costs of commercialization, sufficiency of cash resources, outcomes of legal proceedings, and the need for additional financing.
Investor Verification Checklist
- Verify the FDA's acceptance of the NDA resubmission and confirmation of the Class 2 review designation.
- Monitor the official FDA target action date for the DEXTENZA application.
- Review the Company's most recent quarterly or annual reports for updated cash runway and liquidity status, as this 8-K does not provide financial data.
- Track the resolution of the manufacturing deficiencies previously cited by the FDA.